A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Active:	Yes
Cancer Type:	Eye Cancer Melanoma Unknown Primary	NCT ID:	NCT06581406
Trial Phases:	Phase II Phase III	Protocol IDs:	RP2-202 (primary) NCI-2024-07892
Eligibility:	0 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Replimune Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06581406

Summary

The purpose of this study is to measure the clinical benefits of the combination of RP2
and nivolumab as compared with the combination of nivolumab and ipilimumab in patients
with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor
therapy.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.